FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
|Articles|January 13, 2023
Adare Pharma Solutions Coordinating Quality with Veeva Vault Quality Suite
Author(s)BioPharm International Editors
The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy.
Advertisement
Veeva Systems announced on Jan. 13, 2023 that Adare Pharma Solutions, a contract development and manufacturing (CDMO) with expertise in oral dosage forms, chose Veeva Vault Quality Suite to harmonize quality systems across the organization. This choice can help Adare streamline quality processes, work more effectively with partners and suppliers, and deliver greater visibility into operations to customers.
“As Adare expands its business, standardizing on the technology many of our customers use is a top priority to streamline collaboration,” said Audrey Butler, vice president, global head of quality at Adare Pharma Solutions, in a press release. “Veeva Vault Quality Suite will bring together our global teams on one platform for seamless processes and real-time data access that can help us improve how we work with clients and deliver differentiated services.”
The Vault Quality Suite will help Adare simplify its quality operations across its sites in the United States, France, and Italy. Further, Adare will use Veeva Vault QMS to manage all quality processes, Veeva Vault QualityDocs to control documents and ensure quality, and Veeva Vault Training to drive employee qualifications. This new collaboration helps Adare to manage content, data, and training in a single end-to-end quality system.
“We’re proud to partner with Adare Pharma Solutions to help support their goals of improving services for clients and delivering transformational medicines for patients,” said Ashley Wentworth, senior director, Veeva Vault Quality strategy, in a press release. “With the Veeva Vault Quality Suite, Adare will have a scalable cloud platform that can keep up with evolving industry and customer requirements.”
Source:
Advertisement
Related to this article
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
FDA has effectively paused its Commissioner’s National Priority Voucher pilot and appears to have halted new complete response letter postings, according to reports. HHS says work on the program is ongoing.
A single dose of Zai Lab’s long-acting bispecific ZL-1503 produced at least 90% inhibition of an atopic dermatitis signaling biomarker through Week 12 in healthy volunteers. Its 40- to 50-day half-life supports a target of dosing every 12 weeks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Advertisement
Advertisement
Trending on BioPharm International
1
Zai Lab’s Long-Acting Atopic Dermatitis Bispecific Points to Every-12-Week Dosin
2
FDA Grants Kamau RMAT Designation to Nula-cel for Sickle Cell Disease
3
Ionis Reports 2-Year Donidalorsen (Dawnzera) Data in HAE Prophylaxis
4
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
5